[A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency]

Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5 Suppl 2):44-8.
[Article in Russian]


An assessment of the complex multicenter prospective non-comparative program aimed at studying of efficacy and safety of a new scheme of therapy with cavinton in patients with chronic cerebrovascular insufficiency has been conducted. One hundred and forty-nine patients (46 male, 113 female), aged from 35 to 65 years, have been examined. The treatment started from intravenous infusions of the drug during 7 days as follows: 20, 30, 40, 50, 50, 50 and 50 mg of cavinton solution diluted in 500 ml of physiologic solution with the following peroral taking of cavinton forte in dose 10 mg 3 times daily during 11 weeks. Efficacy of drug was primarily assessed with MMSE and then by SF-36 and CGIC-PGIC. There were significant differences in scores on MMSE and SF-36 before and after treatment and on CGIC-PGIC on the 8th and 90th days of the study. The parenteral and peroral use of cavinton is well-tolerated and has a favorable safety profile.

Publication types

  • Clinical Trial
  • English Abstract
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / therapeutic use
  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / psychology
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Prospective Studies
  • Psychometrics
  • Quality of Life*
  • Surveys and Questionnaires
  • Treatment Outcome
  • Vinca Alkaloids / administration & dosage
  • Vinca Alkaloids / therapeutic use*


  • Calcium Channel Blockers
  • Neuroprotective Agents
  • Vinca Alkaloids
  • vinpocetine